CellCept Shortage Update: What Patients Need to Know in 2026

If you're a transplant patient taking CellCept (mycophenolate mofetil) and you've been struggling to fill your prescription, this update is for you. Here's the current picture on CellCept and generic mycophenolate availability in 2026 — and what you should do if your pharmacy is out of stock.

Current Status: Is CellCept in Shortage in 2026?

Brand-name CellCept manufactured by Genentech is not currently on the FDA's formal drug shortage list. The brand is generally accessible at pharmacies that stock transplant medications, specialty pharmacies, and through mail order.

Generic mycophenolate mofetil is a different story. The American Society of Health-System Pharmacists (ASHP) has documented shortage listings for several major generic manufacturers including Hikma, Mylan, Sandoz, Accord, and Ascend — covering both 250 mg capsules and 500 mg tablets. The situation is not a total nationwide shortage, but supply is uneven and pharmacy-level stock gaps are common.

Meanwhile, generic mycophenolate sodium delayed-release tablets (the Myfortic formulation) have also experienced intermittent shortage listings, though brand Myfortic and some generic versions remain available.

What Does 'Pharmacy-Level Shortage' Mean for You?

When we say supply is uneven, it means the medication is being manufactured and distributed somewhere in the country — but not every pharmacy has it at every moment. You might show up for your refill and be told it's out of stock, even though the same drug is available two pharmacies over.

This distribution unevenness is caused by multiple factors: pharmacies order from different wholesalers, manufacturers have limited their production runs, and some wholesalers are allocating stock rather than filling all orders. The result is a situation that's manageable — but only if you're proactive.

Timeline: How Did We Get Here?

Pre-2022: Mycophenolate mofetil generics were widely available from multiple manufacturers with minimal supply issues.

2022–2023: Manufacturing disruptions at multiple generic facilities began reducing available supply, exacerbated by supply chain pressures affecting the global generic drug market.

2024: ASHP formally listed mycophenolate mofetil capsules and tablets from multiple manufacturers as in shortage, affecting Hikma, Mylan, Sandoz, Accord, and Ascend products.

2025–2026: Supply has partially recovered but remains fragile. Patients continue to report pharmacy-level stock gaps, especially for the 500 mg tablet strength. Brand CellCept remains generally available.

Which CellCept Formulations Are Most Affected?

Most affected: Generic 500 mg tablets from Hikma, Mylan, Sandoz, Accord, and Ascend.

Also affected: Generic 250 mg capsules from the same manufacturers; some generic Myfortic delayed-release formulations.

Generally available: Brand CellCept (Genentech); brand Myfortic (Novartis); some generic manufacturers still supplying the market.

What Should Patients Do Right Now?

Refill early. Begin your refill process 10–14 days before running out. Don't wait until you're down to your last few pills.

Ask for a 90-day supply. Larger fills reduce the frequency of stock-out risk and are often available at lower per-pill cost.

Use your transplant center's specialty pharmacy. Specialty pharmacies that serve transplant programs maintain more reliable CellCept inventory.

Use medfinder to locate pharmacies near you that have your medication in stock, without spending hours calling around yourself.

Never ration or skip doses. If you're running low, call your transplant team immediately. They may be able to provide a bridge supply or emergency prescription.

The Bottom Line for 2026

CellCept supply in 2026 is manageable but requires planning. Brand CellCept is generally available; some generic manufacturers are in shortage. Patients who plan ahead — with early refills, 90-day supplies, and specialty pharmacy relationships — are far less likely to face dangerous supply gaps.

For a deeper explanation of why these shortages happen, see: Why Is CellCept So Hard to Find? [Explained for 2026].